• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Inspections, Compliance, Enforcement, and Criminal Investigations

  • Print
  • Share
  • E-mail
-
-

2010 Warning Letters

Recently Posted | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996

Warning Letters issued in 2010

 

* Not issued: A close-out letter may issue when, based on FDA’s evaluation, the firm has taken corrective action to address the violations contained in the Warning Letter. This procedure applies to Warning Letters issued on or after September 1, 2009.

* N/A: Not applicable, the Warning Letter was issued prior to September 1, 2009.

Read more about warning and close-out letters

Posted on June 22, 2010

Letter Issue Date Company Name Issuing Office Subject Close Out Date
June 16, 2010 Oxford Falls New Orleans District Office Food Labeling/Misbranded June 27, 2012
June 15, 2010 Skogen, John L. Minneapolis District Office Illegal Drug Residue November 15, 2010
June 15, 2010 Union Development Frozen Foods Co., Ltd Center for Food Safety and Applied Nutrition Seafood HACCP/Adulterated/Misbranded Not Issued *
June 14, 2010 Catalina Offshore Products, Inc Los Angeles District Office Seafood HACCP/CGMP for Foods/Adulterated March 14, 2011
June 11, 2010 Optovue Inc. San Francisco District Office CGMP/QSR/Medical Devices/Adulterated/Misbranded February 23, 2012
June 10, 2010 Medefil Incorporated Chicago District Office CGMP/QSR/Medical Devices/Adulterated Not Issued *
June 10, 2010 Nicola Pizza Inc. Philadelphia District Office CGMP for Foods/Labeling/Misbranded Not Issued *
June 10, 2010 Libido Edge Labs, Llc Cincinnati District Office Unapproved New Drug Promotional Claims/Misbranded Not Issued *
June 10, 2010 Clearview Farms Cincinnati District Office Illegal Drug Residue Not Issued *
June 09, 2010 Adamis Pharmaceuticals Center for Drug Evaluation and Research Unapproved New Drug/Misbranded February 15, 2011


 

Contact FDA

301-796-8490
FDA's Office of Critical Path Programs
-
-
-